Structural domains in RNAi

R. Collins,Xiaodong Cheng

DOI: https://doi.org/10.1016/j.febslet.2005.07.072

2005-10-31

FEBS Letters

Abstract:

What problem does this paper attempt to address?

Capecitabine maintenance therapy after induction chemotherapy in newly diagnosed metastatic nasopharyngeal carcinoma: An open-label, randomized, controlled, phase trial.

Guo-Ying Liu,Wang-Zhong Li,De-Shen Wang,Hu Liang,Xing Lv,Yan-Fang Ye,Chong Zhao,Liang-Ru Ke,Mengyun Qiang,Xun Cao,Shu-Hui Lv,Nian Lu,Wei-Xin Bei,Zhuocheng Cai,Xi Chen,Jun-Zhi Xie,Chixiong Liang,Xiang Guo,Weixiong Xia,Xiang Yanqun

DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.6044

IF: 45.3

2021-05-20

Journal of Clinical Oncology

Abstract:6044 Background: Capecitabine maintenance therapy improves outcomes in various tumor types, but minimal data are available on the effect of capecitabine maintenance therapy in metastatic nasopharyngeal carcinoma (NPC). We aimed to investigate whether capecitabine maintenance therapy would prolong the progression-free survival (PFS) of newly diagnosed metastatic NPC, in comparison to best supportive care (BSC). Methods: This was an open-label, randomized, controlled, phase trial. Eligible patients for maintenance randomisation were aged 18-65 years old with newly diagnosed metastatic NPC at the Sun Yat-Sun University Cancer Center (SYSUCC), had completed 4 to 6 cycles of induction chemotherapy as per protocol and had achieved disease control to protocol treatment, including capecitabine. Patients were randomly assigned 1:1 to capecitabine maintenance (oral 1,250 mg/m 2 /day on days 1-14 every 21 days) for up to 24 months with BSC or BSC alone. The primary endpoint was PFS. The secondary endpoints included overall survival, duration of response, objective response rate and adverse effects. Analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT02460419 and is ongoing and no longer recruiting new patients. Results: Between May 16th, 2015, and January 9th, 2020, 140 metastatic NPC patients were screened, and 104 eligible patients were randomly assigned to capecitabine maintenance plus BSC (n = 52) or BSC alone (n = 52). After a median follow-up of 33.1 months (IQR, 21.5-50.7 months), median PFS was 35.2 months in the capecitabine maintenance group and 9.1 months in the BSC group (HR: 0.426; 95%CI: 0.248-0.731, P = 0.001). The most commongrade 3 or 4 adverse events during maintenance therapy were hand-foot syndrome (10.0%), nausea/vomiting (6.0%), fatigue (4.0%), and mucositis (4.0%). Totally 37 deaths occurred during follow-up, 14 (26.9%) in the capecitabine maintenance group and 23 (44.2%) in the BSC group. Overall survival data was immature. No deaths in the capecitabine maintenance group were deemed treatment related. Conclusions: Capecitabine maintenance significantly improved PFS in patients with newly diagnosed metastatic NPC who achieved disease control after induction chemotherapy compared to BSC and exhibited low grade and manageable toxicities. Clinical trial information: NCT02460419.

oncology
Meta-Analysis Of Capecitabine-Based Chemotherapy Versus Capecitabine-Free Chemotherapy In Patients With Metastatic Breast Cancer

Li Zuo,Gang Li,Yingchun Xu,Fengchun Zhang

2016-01-01

Abstract:Objective: Discordant efficacy and safety of capecitabine-based chemotherapy versus capecitabine-free chemotherapy were reported by previous trials. Our meta-analysis aimed to determine the efficacy and safety of capecitabine-based chemotherapy verse capecitabine-free chemotherapy in patients with metastatic breast cancer. Methods: Literatures were searched in Pubmed, Medline and Embase from January 1990 to January 2015 in this study. Studies of parallel group design comparing capecitabine-based chemotherapy and capecitabine-free chemotherapy for metastatic breast cancer were screened. After independent review of 732 citations by 2 authors, ten studies were identified as meeting the inclusion criteria. Results: Our study showed that capecitabine-based chemotherapy had a similar clinical response, partial response, overall response and progression free survival with capecitabine-free chemotherapy. However, patients treated with capecitabine-based chemotherapy had a better overall survival than patients treated with capecitabine-free chemotherapy (OR=0.8, 95% CI: 0.68 to 0.95). Neutropenia (OR=1.22, 95% CI: 1.05-1.41) and leukocytopenia (OR=1.36, 95% CI: 1.13-1.63) occurred less in capecitabine-based chemotherapy group. Significantly more diarrhea (OR=0.46, 95% CI: 0.32-0.65), nausea (OR=0.47, 95% CI: 0.24-0.89) and hand-foot syndrome (OR=0.07, 95% CI: 0.04-0.17) occurred in capecitabine-based chemotherapy group than in capecitabine-free chemotherapy group. Conclusion: Our study indicated that capecitabine-based chemotherapy is as effective as capecitabine-free chemotherapy in patients with metastatic breast cancer with better overall survival and acceptable toxicity profiles.
144O Comparison of Efficacy and Safety of Paclitaxel and Capecitabine Followed by Capecitabine As Maintenance Therapy Versus Cisplatin and Capecitabine Therapy for Advanced Gastric Cancer: a Multicentre, Randomised, Active-Controlled Phase III Study

X. Zhang,L. Shen,Z. Lu,W. Liu,T. Liu,B. Hu,W. Li,Q. Fan,J. Xu,N. Xu,Y. Bai,Y. Pan,Q. Xu,W. Bai,L. Xia,Y. Gao,W. Wang,Y. Shu,G. Dai,J. Feng

DOI: https://doi.org/10.1093/annonc/mdv523.05

IF: 51.769

2015-01-01

Annals of Oncology

Abstract:Aim/Background: Effective chemotherapy with mild toxicity for treatment of advanced gastric cancer is still limited. This study aimed to compare the efficacy and safety of combination therapy of paclitaxel and capecitabine followed by capecitabine monotherapy as maintenance therapy (PACX) versus cisplatin and capecitabine combination therapy (XP) for advanced gastric cancer. Methods: This multicentre, randomised, active-controlled phase III study included 320 patients who were enrolled from 22 clinical sites across different regions of China. Patients were randomly allocated to PACX or XP group in a 1:1 ratio with the following four stratification factors: Karnofsky performance score (≥80/ < 80); resection of primary tumour (yes/no); weight loss within last 3 months (≥5%/ < 5%); and primary tumour site at the gastroesophageal junction (yes/no). The primary endpoint assessed progression-free survival (PFS). The secondary endpoints assessed overall survival (OS), objective response rate (ORR), disease control rate (DCR), quality of life (QoL), and safety. Results: Comparison of PACX and XP groups showed that both median PFS (5.1 versus 5.3 months, respectively; p = 0.40) and median OS (12.6 versus 11.9 months, respectively; p = 0.21) were not different. ORR in PACX group was significantly higher versus XP group (45.4% vs. 31.7%, p = 0.0115), while DCR was similar in both groups (81.6% vs. 80.0%, p = 0.75). Patients receiving PACX showed significantly improved QoL compared with those receiving XP after three cycles of the regimens. The incidences of treatment-associated leukopenia, thrombocytopenia, nausea, vomiting, and reduction in food intake were significantly lower in PACX group than those in XP group (all p < 0.05). Conclusions: These findings suggest that combination therapy of paclitaxel and capecitabine as first-line chemotherapy followed by capecitabine monotherapy as maintenance therapy might be effective and safe in treatment of advanced gastric cancer. Clinical trial identification: NCT01015339 Disclosure: All authors have declared no conflicts of interest.
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.

Jun Ma,Yu-Pei Chen,Ying Sun,Qin Zhou,Kun-Yu Yang,Feng Jin,Xiao-Dong Zhu,Mei Shi,Guoqing Hu,Yan Sun,Hong-Fen Wu,Hui Wu,Qin Lin,Hui Wang,Ye Tian,Ning Zhang,Xicheng Wang,Liangfang Shen,Fangyun Xie,Xu Liu

DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.6003

IF: 45.3

2021-05-20

Journal of Clinical Oncology

Abstract:6003 Background: Patients suffering from locoregionally advanced nasopharyngeal carcinoma (NPC) commonly develop disease recurrence, despite a high rate of complete clinical remission after standard of care (concurrent cisplatin-radiotherapy, with or without induction chemotherapy). The benefit of additional adjuvant chemotherapy remains unclear. Methods: Patients with high-risk locoregionally advanced NPC (stage III to IVA, excluding T3-4N0 and T3N1), and with no locoregional disease or distant metastasis after definitive chemoradiotherapy, were eligible. They were randomly assigned (1:1) within 12 to 16 weeks after the last radiation dose to receive either capecitabine at a dose of 650 mg/m 2 twice daily for 1 year (metronomic capecitabine group) or observation (standard-therapy group). The primary end point was recurrence-free survival (RFS). The calculated sample size was 201 per group, with an 80% power (two-sided α 0.05) to detect a target hazard ratio (HR) of 0.52. Results: A total of 406 patients underwent randomization, comprising 204 in the metronomic capecitabine group and 202 in the standard-therapy group. After a median follow-up of 36 months (corresponding to 43 months when calculated from the start of standard therapy), the estimated 3-year RFS was 85.9% in the metronomic capecitabine group, as compared with 76.5% in the standard-therapy group (intention-to-treat population; HR 0.51, 95% confidence interval 0.32–0.81; P = 0.003). The incidence of grade 3 adverse events was 17.4% in the metronomic capecitabine group and 5.5% in the standard-therapy group; hand-foot syndrome was the most common adverse event related to capecitabine (9.0%). One grade 4 neutropenia occurred in the metronomic capecitabine group. Neither group sufferd from treatment-related deaths. During treatment, there was no clinically meaningful deterioration of health-related quality of life associated with the use of metronomic adjuvant capecitabine. Conclusions: The addition of metronomic capecitabine as adjuvant therapy to chemoradiotherapy significantly improved RFS in locoregionally advanced NPC, with a manageable safety profile and no compromise to quality of life. Clinical trial information: NCT02958111. [Table: see text]

oncology
WITHDRAWN: Interim Analysis of a Prospective Randomized Non-Inferiority Trial of Cisplatin and Fluorouracil Induction Chemotherapy with or Without Docetaxel in Nasopharyngeal Carcinoma

Ting Jin,Wei-feng Qin,Feng Jiang,Qi-feng Jin,Qi-chun Wei,Xiu-wen Tang,Yong-shi Jia,Xiao-nan Sun,Wen-feng Li,Xing-lai Feng,Xiao-zhong Chen

DOI: https://doi.org/10.18632/oncotarget.10903

2016-01-01

Oncotarget

Abstract:In this study, we aim to compare the progression-free survival (PFS) rates and side effects of induction chemotherapy based on docetaxel, cisplatin and fluorouracil (TPF) versus cisplatin and fluorouracil (PF) in patients with locoregionally-advanced nasopharyngeal carcinoma who received subsequent chemoradiotherapy.We randomly assigned 276 patients with stage III or IV NPC (without distant metastases) to receive either TPF or PF induction chemotherapy, followed by cisplatin-based chemoradiotherapy every 3 weeks and intensity-modulated radiation therapy for 5 days per week.After a minimum of 2 years follow-up, a PFS benefit was observed for TPF compared to PF, though this difference was not statistically significant (84.5% vs. 77.9%,P = 0.380).Due to increased frequencies of grade 3 or 4 neutropenia and diarrhea, significantly more patients in the TPF group required treatment delays and dose modifications.Our findings suggest that PF induction chemotherapy has substantially better tolerance and compliance rates than TPF induction chemotherapy.However, the treatment efficacy of PF is not superior to TPF induction chemotherapy in patients with locoregionally-advanced NPC (ClinicalTrials.govnumber, NCT01536223).www.impactjournals.com/oncotarget
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial

Yu-Pei Chen,Xu Liu,Qin Zhou,Kun-Yu Yang,Feng Jin,Xiao-Dong Zhu,Mei Shi,Guo-Qing Hu,Wei-Han Hu,Yan Sun,Hong-Fen Wu,Hui Wu,Qin Lin,Hui Wang,Ye Tian,Ning Zhang,Xi-Cheng Wang,Liang-Fang Shen,Zheng-Zheng Liu,Jing Huang,Xiu-Ling Luo,Ling Li,Jian Zang,Qi Mei,Bao-Min Zheng,Dan Yue,Jing Xu,San-Gang Wu,Yan-Xia Shi,Yan-Ping Mao,Lei Chen,Wen-Fei Li,Guan-Qun Zhou,Rui Sun,Rui Guo,Yuan Zhang,Cheng Xu,Jia-Wei Lv,Ying Guo,Hui-Xia Feng,Ling-Long Tang,Fang-Yun Xie,Ying Sun,Jun Ma,Yu-Pei Chen,Xu Liu,Qin Zhou,Kun-Yu Yang,Feng Jin,Xiao-Dong Zhu,Mei Shi,Guo-Qing Hu,Wei-Han Hu,Yan Sun,Hong-Fen Wu,Hui Wu,Qin Lin,Hui Wang,Ye Tian,Ning Zhang,Xi-Cheng Wang,Liang-Fang Shen,Zheng-Zheng Liu,Jing Huang,Xiu-Ling Luo,Ling Li,Jian Zang,Qi Mei,Bao-Min Zheng,Dan Yue,Jing Xu,San-Gang Wu,Yan-Xia Shi,Yan-Ping Mao,Lei Chen,Wen-Fei Li,Guan-Qun Zhou,Rui Sun,Rui Guo,Yuan Zhang,Cheng Xu,Jia-Wei Lv,Ying Guo,Hui-Xia Feng,Ling-Long Tang,Fang-Yun Xie,Ying Sun,Jun Ma

DOI: https://doi.org/10.1016/s0140-6736(21)01123-5

IF: 202.731

2021-07-01

The Lancet

Abstract:BACKGROUND: Patients with locoregionally advanced nasopharyngeal carcinoma have a high risk of disease relapse, despite a high proportion of patients attaining complete clinical remission after receiving standard-of-care treatment (ie, definitive concurrent chemoradiotherapy with or without induction chemotherapy). Additional adjuvant therapies are needed to further reduce the risk of recurrence and death. However, the benefit of adjuvant chemotherapy for nasopharyngeal carcinoma remains controversial, highlighting the need for more effective adjuvant treatment options.METHODS: This multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial was done at 14 hospitals in China. Patients (aged 18-65 years) with histologically confirmed, high-risk locoregionally advanced nasopharyngeal carcinoma (stage III-IVA, excluding T3-4N0 and T3N1 disease), no locoregional disease or distant metastasis after definitive chemoradiotherapy, an Eastern Cooperative Oncology Group performance status of 0 or 1, sufficient haematological, renal, and hepatic function, and who had received their final radiotherapy dose 12-16 weeks before randomisation, were randomly assigned (1:1) to receive either oral metronomic capecitabine (650 mg/m2 body surface area twice daily for 1 year; metronomic capecitabine group) or observation (standard therapy group). Randomisation was done with a computer-generated sequence (block size of four), stratified by trial centre and receipt of induction chemotherapy (yes or no). The primary endpoint was failure-free survival, defined as the time from randomisation to disease recurrence (distant metastasis or locoregional recurrence) or death due to any cause, in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of capecitabine or who had commenced observation. This trial is registered with ClinicalTrials.gov, NCT02958111.FINDINGS: Between Jan 25, 2017, and Oct 25, 2018, 675 patients were screened, of whom 406 were enrolled and randomly assigned to the metronomic capecitabine group (n=204) or to the standard therapy group (n=202). After a median follow-up of 38 months (IQR 33-42), there were 29 (14%) events of recurrence or death in the metronomic capecitabine group and 53 (26%) events of recurrence or death in the standard therapy group. Failure-free survival at 3 years was significantly higher in the metronomic capecitabine group (85·3% [95% CI 80·4-90·6]) than in the standard therapy group (75·7% [69·9-81·9]), with a stratified hazard ratio of 0·50 (95% CI 0·32-0·79; p=0·0023). Grade 3 adverse events were reported in 35 (17%) of 201 patients in the metronomic capecitabine group and in 11 (6%) of 200 patients in the standard therapy group; hand-foot syndrome was the most common adverse event related to capecitabine (18 [9%] patients had grade 3 hand-foot syndrome). One (<1%) patient in the metronomic capecitabine group had grade 4 neutropenia. No treatment-related deaths were reported in either group.INTERPRETATION: The addition of metronomic adjuvant capecitabine to chemoradiotherapy significantly improved failure-free survival in patients with high-risk locoregionally advanced nasopharyngeal carcinoma, with a manageable safety profile. These results support a potential role for metronomic chemotherapy as an adjuvant therapy in the treatment of nasopharyngeal carcinoma.FUNDING: The National Natural Science Foundation of China, the Key-Area Research and Development Program of Guangdong Province, the Natural Science Foundation of Guangdong Province, the Innovation Team Development Plan of the Ministry of Education, and the Overseas Expertise Introduction Project for Discipline Innovation.TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

medicine, general & internal
Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma.

Ting Jin,Wei-Feng Qin,Feng Jiang,Qi-Feng Jin,Qi-Chun Wei,Yong-Shi Jia,Xiao-Nan Sun,Wen-Feng Li,Xiao-Zhong Chen

DOI: https://doi.org/10.1016/j.tranon.2019.01.002

IF: 4.803

2019-01-01

Translational Oncology

Abstract:In this study, we aim to compare the progression-free survival (PFS) rates and side effects of induction chemotherapy based on docetaxel, cisplatin and fluorouracil (TPF) versus cisplatin and fluorouracil (PF) in patients with locoregionally-advanced nasopharyngeal carcinoma who received subsequent chemoradiotherapy. We randomly assigned 278 patients with stage III or IV NPC (without distant metastases) to receive either TPF or PF induction chemotherapy, followed by cisplatin-based chemoradiotherapy every 3 weeks and intensity-modulated radiation therapy for 5 days per week. After a minimum of 2 years follow-up, a PFS benefit was observed for TPF compared to PF, though this difference was not statistically significant (84.5% vs. 77.9%, P = .380). Due to increased frequencies of grade 3 or 4 neutropenia and diarrhea, significantly more patients in the TPF group required treatment delays and dose modifications. Our findings suggest that PF induction chemotherapy has substantially better tolerance and compliance rates than TPF induction chemotherapy. However, the treatment efficacy of PF is not superior to TPF induction chemotherapy in patients with locoregionally-advanced NPC (ClinicalTrials.gov number, NCT01536223).
Effects of Oral Maintenance Chemotherapy and Predictive Value of Circulating EBV DNA in Metastatic Nasopharyngeal Carcinoma

Han Zhou,Tianzhu Lu,Qiaojuan Guo,Yan Chen,Mengwei Chen,Yansong Chen,Yingying Lin,Chuanben Chen,Liqin Ma,Yun Xu,Shaojun Lin,Jianji Pan

DOI: https://doi.org/10.1002/cam4.2926

IF: 4.711

2020-01-01

Cancer Medicine

Abstract:Abstract Background/Objectives Oral maintenance chemotherapy can effectively prolong overall survival (OS) in many types of metastatic cancer, but its role in metastatic nasopharyngeal carcinoma (mNPC) is unclear. In this study, the efficacy of oral maintenance chemotherapy in mNPC and the effectiveness of circulating tumor EBV‐DNA for screening patients were evaluated. Methods Between June 2016 and December 2017, 141 patients with mNPC who received platinum‐based systemic chemotherapy were included (median follow‐up time, 21 months). Patients were classified into two groups according to the administration of oral maintenance chemotherapy. Plasma samples were collected before, during, and after treatment for the measurement of circulating EBV DNA. Results The 2‐year OS was higher for patients who received maintenance chemotherapy than for patients without maintenance chemotherapy (78.9% vs 62.7%, P = .016). Patients with undetectable posttreatment EBV‐DNA after 4‐6 cycles of systemic chemotherapy (n = 73) had a higher 2‐year OS than that of patients with detectable EBV‐DNA (n = 68) (82.16% vs 51.45%, P = .001). For patients with undetectable posttreatment EBV‐DNA, OS was better for those with maintenance chemotherapy than for those without (86.7% vs 73%, P = .027). For patients with detectable posttreatment EBV‐DNA, maintenance chemotherapy did not improve outcomes (49.5% vs 55.4%, P = .824). The most common acute events were hematological toxicity, and all were tolerable and curable. Conclusions Oral maintenance chemotherapy with S1 or capecitabine can improve OS in mNPC. Posttreatment EBV‐DNA was not only an independent prognosis factor for mNPC but also can screen out beneficiaries of maintenance chemotherapy.
Colour parameters and shade correspondence of CAD-CAM ceramic systems.

Á. Della Bona,O. Pecho,R. Ghinea,J. C. Cardona,M. M. Pérez

DOI: https://doi.org/10.1016/j.jdent.2015.02.015

2015-06-01

Abstract:
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Recurrent or Metastatic Nasopharyngeal Carcinoma: a Multicentre, Randomised, Open-Label, Phase 3 Trial.

Li Zhang,Yan Huang,Shaodong Hong,Yunpeng Yang,Gengsheng Yu,Jun Jia,Peijian Peng,Xuan Wu,Qing Lin,Xuping Xi,Jiewen Peng,Mingjun Xu,Dongping Chen,Xiaojun Lu,Rensheng Wang,Xiaolong Cao,Xiaozhong Chen,Zhixiong Lin,Jianping Xiong,Qin Lin,Conghua Xie,Zhihua Li,Jianji Pan,Jingao Li,Shixiu Wu,Yingni Lian,Quanlie Yang,Chong Zhao

DOI: https://doi.org/10.1016/s0140-6736(16)31388-5

2016-01-01

Abstract:Background Outcomes are poor for patients with recurrent or metastatic nasopharyngeal carcinoma and no well established first-line chemotherapy is available for the disease. We compared the efficacy and safety of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.Methods In this multicentre, randomised, open-label, phase 3 trial, patients with recurrent or metastatic nasopharyngeal carcinoma were recruited from 22 hospitals in China. Key inclusion criteria were Eastern Cooperative Oncology Group performance status of 0 or 1, adequate organ function, and measurable lesions according to Response Evaluation Criteria in Solid Tumors version 1.1. Patients were randomly assigned in a 1: 1 ratio to receive either gemcitabine (1 g/m(2) intravenously on days 1 and 8) and cisplatin (80 mg/m(2) intravenously on day 1), or fluorouracil (4 g/m(2) in continuous intravenous infusion over 96 h) and cisplatin (80 mg/m(2) on day 1 given intravenously) once every 3 weeks for a maximum of six cycles. The randomisation was done centrally via an interactive phone response system using block randomisation with a size of six. The primary endpoint was progression-free survival assessed by the independent image committee in the intention-to-treat population. Safety analyses were done in patients who received at least one cycle of study drug. This study is ongoing and is registered with ClinicalTrials. gov, number NCT01528618.Findings Between Feb 20, 2012, and Oct 30, 2015, 362 patients were randomly assigned to a group (181 to the gemcitabine [ plus cisplatin] group and 181 to the fluorouracil [plus cisplatin] group). Median follow-up time for progression-free survival was 19.4 months (IQR 12.1-35.6). The median progression-free survival was 7.0 months (4.4-10.9) in the gemcitabine group and 5.6 months (3.0-7.0) in the fl uorouracil group (hazard ratio [HR] 0.55 [ 95% CI 0.44-0.68]; p< 0.0001). A total of 180 patients in the gemcitabine group and 173 patients in the fl uorouracil group were included in the safety analysis. Significantly different treatment-related grade 3 or 4 adverse events between the gemcitabine and fl uorouracil groups were leucopenia (52 [29%] vs 15 [9%]; < 0.0001), neutropenia (41 [23%] vs 23 [13%]; p= 0.0251), thrombocytopenia (24 [13%] vs three [2%]; p= 0.0007), and mucosal inflammation (0 vs 25 [14%]; < 0.0001). Serious treatment-related adverse events occurred in seven (4%) patients in the gemcitabine group and ten (6%) in the fluorouracil group. Six (3%) patients in the gemcitabine group and 14 (8%) patients in the fluorouracil group discontinued treatment because of drug-related adverse events. No treatment-related deaths occurred in either group.Interpretation Gemcitabine plus cisplatin prolongs progression-free survival in patients with recurrent or metastatic nasopharyngeal carcinoma. The results establish gemcitabine plus cisplatin as the standard first-line treatment option for this population.
The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial

Lin-Quan Tang,Xiao-Yun Li,Zhi-Ming Li,Zhi-Gang Liu,Miao-Zhen Lin,Huan Zhou,Qi-Wen Yu,Jian Zhou,Chong Zhao,Ze-Bin Chen,Xi-Cheng Wang,Jia-Yu Peng,Qiu-Yan Chen,Wen-Feng Fang,Yun-Peng Yang,Bei Zhang,Liang-Ping Xia,Pi-Li Hu,Wei-Han Hu,Yi-Jie Li,Hai-Qiang Mai,Xiu-Yu Cai

DOI: https://doi.org/10.1186/s12916-023-02790-1

2023-03-16

Abstract:Background: Previous studies have shown that monotherapy with apatinib, an oral tyrosine kinase inhibitor, has promising efficacy for treating recurrent or metastatic (RM) nasopharyngeal carcinoma (NPC) patients. In this study, we aimed to assess the efficacy and safety of apatinib combined with capecitabine as a second-line therapy or beyond for treating RM-NPC patients who failed the first-line platinum-based chemotherapy. Methods: In this single-arm, phase II study, we enrolled RM-NPC patients who had at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). The sample size was determined using Simon's two-stage design. All patients were administered with apatinib 500 mg once daily and capecitabine 1000 mg/m2 twice per day on days 1-14 of each 21-day cycle. The primary endpoint was the objective response rate (ORR), and the secondary endpoints comprised disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. Results: We enrolled 64 patients from September 2018 to August 2020. The ORR and DCR were 39.1% (95% CI, 27.1-52.1) and 85.9% (95% CI, 75.0-93.4), respectively. The median DoR was 14.4 months (95% CI, 7.8-21.0). As of April 20, 2021, the median follow-up duration was 12.0 months. The median PFS was 7.5 months (95% CI, 5.0-10.0) and the median OS was 15.7 months (95% CI, 11.3-20.1). The most common toxicities of any grade were anemia (75.0%), hand-foot syndrome (65.6%), and proteinuria (64.0%). Grade 3-4 toxicities were observed in 36 (56.3%) patients, with hypertension (14.1%), mucositis (12.4%), and fatigue (10.9%) most commonly observed. Conclusions: Apatinib plus capecitabine shows promising efficacy as a second-line treatment option in pretreated platinum-refractory RM-NPC patients. Dose selection of this combination needs further investigation considering the toxicity. Trial registration: Chi-CTR1800017229.
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment

Xi Wang,Shu-Sen Wang,Heng Huang,Li Cai,Li Zhao,Rou-Jun Peng,Ying Lin,Jun Tang,Jian Zeng,Le-Hong Zhang,Yong-Li Ke,Xian-Ming Wang,Xin-Mei Liu,Qian-Jun Chen,An-Qin Zhang,Fei Xu,Xi-Wen Bi,Jia-Jia Huang,Ji-Bin Li,Dan-Mei Pang,Cong Xue,Yan-Xia Shi,Zhen-Yu He,Huan-Xin Lin,Xin An,Wen Xia,Ye Cao,Ying Guo,Yan-Hong Su,Xin Hua,Xin-Yue Wang,Ruo-Xi Hong,Kui-Kui Jiang,Chen-Ge Song,Zhang-Zan Huang,Wei Shi,Yong-Yi Zhong,Zhong-Yu Yuan,,

DOI: https://doi.org/10.1001/jama.2020.23370

IF: 11.816

2021-01-05

JAMA

Abstract:Question Does therapy with low-dose capecitabine maintenance after standard adjuvant chemotherapy reduce the risk of relapse and death in early-stage triple-negative breast cancer?Findings In this randomized clinical trial of 434 women with early-stage triple-negative breast cancer who received standard adjuvant treatment, low-dose capecitabine maintenance therapy for 1 year, compared with observation, resulted in significantly higher 5-year disease-free survival (82.8% vs 73.0%; hazard ratio for risk of recurrence or death, 0.64).Meaning Among women with early-stage triple-negative breast cancer, maintenance therapy with low-dose capecitabine significantly improved disease-free survival at 5 years.Importance Among all subtypes of breast cancer, triple-negative breast cancer has a relatively high relapse rate and poor outcome after standard treatment. Effective strategies to reduce the risk of relapse and death are needed.Objective To evaluate the efficacy and adverse effects of low-dose capecitabine maintenance after standard adjuvant chemotherapy in early-stage triple-negative breast cancer.Design, Setting, and Participants Randomized clinical trial conducted at 13 academic centers and clinical sites in China from April 2010 to December 2016 and final date of follow-up was April 30, 2020. Patients (n = 443) had early-stage triple-negative breast cancer and had completed standard adjuvant chemotherapy.Interventions Eligible patients were randomized 1:1 to receive capecitabine (n = 222) at a dose of 650 mg/m2 twice a day by mouth for 1 year without interruption or to observation (n = 221) after completion of standard adjuvant chemotherapy.Main Outcomes and Measures The primary end point was disease-free survival. Secondary end points included distant disease-free survival, overall survival, locoregional recurrence-free survival, and adverse events.Results Among 443 women who were randomized, 434 were included in the full analysis set (mean [SD] age, 46 [9.9] years; T1/T2 stage, 93.1%; node-negative, 61.8%) (98.0% completed the trial). After a median follow-up of 61 months (interquartile range, 44-82), 94 events were observed, including 38 events (37 recurrences and 32 deaths) in the capecitabine group and 56 events (56 recurrences and 40 deaths) in the observation group. The estimated 5-year disease-free survival was 82.8% in the capecitabine group and 73.0% in the observation group (hazard ratio [HR] for risk of recurrence or death, 0.64 [95% CI, 0.42-0.95]; P = .03). In the capecitabine group vs the observation group, the estimated 5-year distant disease-free survival was 85.8% vs 75.8% (HR for risk of distant metastasis or death, 0.60 [95% CI, 0.38-0.92]; P = .02), the estimated 5-year overall survival was 85.5% vs 81.3% (HR for risk of death, 0.75 [95% CI, 0.47-1.19]; P = .22), and the estimated 5-year locoregional recurrence-free survival was 85.0% vs 80.8% (HR for risk of locoregional recurrence or death, 0.72 [95% CI, 0.46-1.13]; P = .15). The most common capecitabine-related adverse event was hand-foot syndrome (45.2%), with 7.7% of patients experiencing a grade 3 event.Conclusions and Relevance Among women with early-stage triple-negative breast cancer who received standard adjuvant treatment, low-dose capecitabine maintenance therapy for 1 year, compared with observation, resulted in significantly improved 5-year disease-free survival.Trial Registration ClinicalTrials.gov Identifier: <a href="https://clinicaltrials.gov/ct2/show/NCT01112826">NCT01112826</a>

medicine, general & internal
Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized controlled phase III trial.

Jingjing Miao,Lin Wang,Sze Huey Tan,Jin-Gao Li,Junlin Yi,Ye Zhang,Xiaochang Gong,Xiang Yanqun,Qiu-Yan Chen,Mingyuan Chen,Xing Lv,Weixiong Xia,Lin-Quan Tang,Xiao-Wu Deng,Xiang Guo,Hai-Qiang Mai,Fei Han,Melvin Lee Kiang Chua,Chong Zhao

DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.6005

IF: 45.3

2021-05-20

Journal of Clinical Oncology

Abstract:6005 Background: We conducted a multicenter, randomized controlled phase III clinical trial (NCT02143388) to investigate the efficacy and toxicity of adjuvant capecitabine (AC) in addition to concurrent cisplatin and radiotherapy (CCRT) compared to CCRT alone in high-risk locoregionally advanced nasopharyngeal carcinoma (LANPC) patients. Methods: Eligibility criteria included AJCC/UICC 7 th ed TNM stage III-IVb and one of the following features: T3-4N2 or T1-4N3 or pre-treatment plasma EBV DNA concentration of >20,000 copy/ml or gross primary tumor volume (GTVnx) of >30 cm 3 or a maximum standard uptake value (SUVmax) of >10.0 by 18 FDG PET-CT within the primary tumor or multiple neck node metastases, with any larger than 4 cm. All patients were randomly assigned in a 1:1 ratio to receive CCRT (3-weekly cisplatin at 100 mg/m 2 for 2-3 cycles) followed by AC (1000 mg/m 2 bi-daily for 14 days every 21-day cycle for 8 cycles), or CCRT alone. The prescribed radiation doses were 68-72 Gy/30-32 fractions to the PTVnx, 60-68 Gy/30-32 fractions to PTVnd, 60-64Gy/30-32 fractions to PTV high-risk , 54-58Gy/30-32 fractions to PTV low-risk . Primary end point was failure-free survival (FFS). Results: Between Mar 2014 to Jul 2018, 180 patients were recruited (90 patients in CCRT+AC arm and 90 in CCRT alone arm). All patients completed RT and ≥2 cycles of concurrent cisplatin in both treatment arms (cumulative dose intensities for cisplatin were 200 mg/m 2 in both arms). 85 (94.4%) patients went on to receive AC, with 71 (78.9%) patients completing 8 cycles; 19 (22.4%) patients had dose reduction of AC. With a median follow-up of 44.8 mo, the 3-y FFS was significantly superior in the CCRT+AC arm than the CCRT arm for the intention-to-treat cohort (87.7% vs 73.3%; HR: 0.52 [95% CI: 0.29-0.77], P = 0.037). 3-year overall, distant metastasis-free and locoregional relapse-free survival were 92.6% vs 88.9% (HR [95% CI]: 0.66 [0.28-1.59]), 88.8% vs. 81.1% (HR: 0.67 [0.33-1.33]) and 91.5% vs 80.0% (HR: 0.50 [0.25-1.00]), respectively. Incidences of G3-4 acute toxicities were 57.8% (52 of 90) in CCRT+AC arm and 51.1% (46 of 90) in CCRT alone arm, with a higher incidence of hand foot syndrome (3.5% vs 0%), xerostomia (11.1% vs 3.3%), mucositis (23.3% vs 16.7%), and anemia (5.6% vs 2.2%) in the CCRT+AC arm. G3-4 late toxicities occurred in 13.3% (12 of 90) and 9.0% (8 of 89), respectively. Conclusions: The addition of capecitabine to CCRT conferred a superior disease control than CCRT alone in high-risk LANPC. Survivals in ITT and PP set. Clinical trial information: NCT02143388. [Table: see text]

oncology
Maintenance intervention to improve survival in patients with metastatic nasopharyngeal carcinoma who benefit from first-line treatment: A prospective multicenter randomized controlled clinical study.

Ying Lu,Haixin Huang,Hui Yang,Xiaohua Hu,Xianbing Feng,Changjie Huang

DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.6035

IF: 45.3

2021-05-20

Journal of Clinical Oncology

Abstract:6035 Background: The role of drug maintenance intervention in improving survival outcomes remains controversial.To investigate the safety and effect of Tegafur(S1) maintenance intervention in patients with metastatic nasopharyngeal carcinoma who benefit from the first-line treatment in a multicenter randomized controlled study, and to identify the related biological prognostic factors and guide the individualized treatment choice. Methods: Patients with metastatic nasopharyngeal carcinoma in the Fourth Affiliated Hospital of Guangxi Medical University and other cancer centers who met the inclusion criteria were randomly divided into maintenance therapy group: S1 maintenance therapy until disease progression or intolerance; Observation group: follow-up to disease progression. PFS, overall survival (OS) and adverse reactions of S1 maintenance therapy were compared between the two groups. The correlation between EBV-DNA, human serum amyloid A (SAA) and prognosis was evaluated. Results: Follow-up was conducted to May 2020, with a median follow-up of 19.8 months (6.1-51.3 months), 183 cases were evaluable (88 cases in S1 maintenance treatment group, 95 cases in observation group). Compared with the observation group, the S1 maintenance treatment group significantly increased patients' median PFS (16.2 months vs. 8.7 months, P < 0.001) and median OS (32.1 months vs. 18.2 months, P < 0.001). Reduced the risk of poor prognosis for PFS and OS (PFS: HR 0.305, 95%CI 0.211-0.441, < 0.001; OS: HR 0.363, 95%CI 0.238-0.553, P < 0.001). In the maintenance treatment group, the median S1 treatment lasted for 14 courses (4-58 courses), and the main adverse reactions were grade 1 skin pigmentation, oral mucositis, hand-foot syndrome, nausea, etc. No grade 4 toxic reaction occurred, and it was well tolerated. Compared with observation patients with negative EBV-DNA, observation patients with positive EBV-DNA had a higher risk of poor prognosis for PFS (HR 1.764, 95%CI 1.078-2.887, P = 0.024). The risk of poor prognosis in patients with positive EBV-NDA was significantly reduced by 61.1% ( < 0.001) for PFS and 65.5% (P = 0.001) for OS (P = 0.001). Compared with the observation group with stable SAA expression, S1 maintenance therapy significantly improved the prognosis of patients. Patients with continuous decline in SAA had a 61.9% lower risk of poor prognosis in PFS (P < 0.001) and a 60.2% lower risk of poor prognosis in OS (P = 0.007). Conclusions: For patients with metastatic nasopharyngeal carcinoma who benefit from first-line treatment, maintenance therapy of S1 can significantly improve the survival prognosis and is well tolerated. Patients with positive EBV-DNA and continuous decline in SAA may benefit more from maintenance intervention. Clinical trial information: ChiCTR-IOR-16007939.

oncology
Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma

Wang-Zhong Li,Xing Lv,Dan Hu,Shu-Hui Lv,Guo-Ying Liu,Hu Liang,Yan-Fang Ye,Wen Yang,Han-Xiong Zhang,Tai-Ze Yuan,De-Shen Wang,Nian Lu,Liang-Ru Ke,Wu-Bing Tang,Li-Hua Tong,Zhi-Jie Chen,Ting Liu,Ka-Jia Cao,Hao-Yuan Mo,Ling Guo,Chong Zhao,Ming-Yuan Chen,Qiu-Yan Chen,Pei-Yu Huang,Rui Sun,Fang Qiu,Dong-Hua Luo,Lin Wang,Yi-Jun Hua,Lin-Quan Tang,Chao-Nan Qian,Hai-Qiang Mai,Xiang Guo,Yan-Qun Xiang,Wei-Xiong Xia

DOI: https://doi.org/10.1001/jamaoncol.2022.0122

IF: 33.006

2022-03-24

JAMA Oncology

Abstract:Question Does chemotherapy with paclitaxel, cisplatin, and capecitabine (TPC) improve failure-free survival compared with cisplatin and fluorouracil (PF) as induction treatment prior to concurrent chemoradiotherapy for patients with stage IVA to IVB nasopharyngeal carcinoma?Findings In this phase 3 randomized clinical trial of 238 patients with stage IVA to IVB nasopharyngeal carcinoma, induction chemotherapy with 2 cycles of TPC followed by 2 cycles of concurrent chemoradiotherapy resulted in a statistically significant improvement in failure-free survival compared with 2 cycles of PF followed by 2 cycles of concurrent chemoradiotherapy, with no increase in the toxicity profile.Meaning Induction chemotherapy with TPC is more efficacious than that with PF for patients with stage IVA to IVB nasopharyngeal carcinoma.Importance Induction chemotherapy added to concurrent chemoradiotherapy significantly improves survival for patients with locoregionally advanced nasopharyngeal carcinoma, but the optimal induction regimen remains unclear.Objective To determine whether induction chemotherapy with paclitaxel, cisplatin, and capecitabine (TPC) improves survival vs cisplatin and fluorouracil (PF) prior to chemoradiotherapy for patients with stage IVA to IVB nasopharyngeal carcinoma.Design, Setting, and Participants This randomized, open-label, phase 3 clinical trial recruited 238 patients at 4 hospitals in China from October 20, 2016, to August 29, 2019. Patients were 18 to 65 years of age with treatment-naive, nonkeratinizing stage IVA to IVB nasopharyngeal carcinoma and an Eastern Cooperative Oncology Group performance status of 0 to 1.Interventions Patients were randomly assigned (1:1) to receive induction chemotherapy with two 21-day cycles of TPC (intravenous paclitaxel [150 mg/m2, day 1], intravenous cisplatin [60 mg/m2, day 1], and oral capecitabine [1000 mg/m2 orally twice daily, days 1-14]) or PF (intravenous cisplatin [100 mg/m2, day 1] and fluorouracil [800 mg/m2 daily, days 1-5]), followed by chemoradiotherapy.Main Outcomes and Measures The primary end point was failure-free survival in the intention-to-treat population. Secondary end points included distant metastasis–free survival, locoregional relapse–free survival, overall survival, tumor response, and safety.Results Overall, 238 eligible patients (187 men [78.6%]; median age, 45 years [range, 18-65 years]) were randomly assigned to receive TPC (n = 118) or PF (n = 120). The median follow-up duration was 48.4 months (IQR, 39.6-53.3 months). Failure-free survival at 3 years was 83.5% (95% CI, 77.0%-90.6%) in the TPC group and 68.9% (95% CI, 61.1%-77.8%) in the PF group (stratified hazard ratio [HR] for recurrence or death, 0.47; 95% CI, 0.28-0.79; P = .004). Induction with the TPC regimen resulted in a significant reduction in the risk of distant metastases (stratified HR, 0.49 [95% CI, 0.24-0.98]; P = .04) and locoregional recurrence (stratified HR, 0.40 [95% CI, 0.18-0.93]; P = .03) compared with the PF regimen. However, there was no effect on early overall survival (stratified HR, 0.45 [95% CI, 0.17-1.18]; P = .10). The incidences of grade 3 to 4 acute adverse events and late-onset toxicities were 57.6% (n = 68) and 13.6% (16 of 118), respectively, in the TPC group and 65.8% (n = 79) and 17.9% (21 of 117), respectively, in the PF group. One treatment-related death occurred in the PF group.Conclusions and Relevance This randomized clinical trial found that induction chemotherapy with 2 cycles of TPC for patients with stage IVA to IVB nasopharyngeal carcinoma improved failure-free survival compared with 2 cycles of PF, with no increase in the toxicity profile.Trial Registration ClinicalTrials.gov Identifier: NCT02940925

oncology
Maintenance metronomic chemotherapy for metastatic/recurrent nasopharyngeal carcinoma

Chih‐Wen Twu,Po‐Ju Lin,Hsiao‐Hui Tsou,Yi‐Chun Liu,Rong‐San Jiang,Kai‐Li Liang,Tian‐Yun Lin,Wen‐Yi Wang,Jin‐Ching Lin

DOI: https://doi.org/10.1002/hed.27044

2022-04-01

Head and Neck

Abstract:BackgroundWe investigated the survival impact and toxicity of maintenance metronomic chemotherapy in patients with metastatic/recurrent nasopharyngeal carcinoma (met/rec NPC).MethodsNinety‐eight patients with met/rec NPC were first salvaged by IV cisplatin‐based chemotherapy and showed nonprogression disease; then maintenance metronomic chemotherapy for at least 12 months was recommended. We analyzed the treatment outcome between patients who received (n = 51) and did not receive (n = 47) maintenance chemotherapy.ResultsBaseline patient characteristics showed no significant differences between both arms. Median overall survival for patients with and without maintenance chemotherapy was 36.0 and 12.3 months, respectively (p
Effects of Induction Docetaxel, Platinum, and Fluorouracil Chemotherapy in Patients with Stage III or IVA/B Nasopharyngeal Cancer Treated with Concurrent Chemoradiation Therapy: Final Results of 2 Parallel Phase 2 Clinical Trials

L. Kong,C. Hu,Y. Guo,Y. Zhang,J. J. Lu

DOI: https://doi.org/10.1002/cncr.30566

IF: 6.9209

2017-01-01

Cancer

Abstract:BACKGROUND: The effects of docetaxel, platinum, and fluorouracil (TPF) induction chemotherapy plus concurrent chemoradiotherapy (CCRT) on locoregionally advanced nasopharyngeal cancer (NPC) are unclear. This study examined the long-term outcomes of the addition of this regimen to CCRT for stage III and IVA/B NPC. METHODS: Two parallel, single-arm phase 2 trials were performed synchronously to evaluate the efficacy and toxicity of TPF-based induction chemotherapy in patients with stage III or IVA/B NPC. The induction chemotherapy, which preceded standard intensity-modulated radiation therapy/platinum-based chemoradiation, consisted of 3 cycles of docetaxel (75mg/m(2) on day 1), cisplatin (75mg/m(2) on day 1), and a continuous infusion of fluorouracil (500mg/m(2)/d on days 1-5) every 4 weeks. The primary endpoint for both trials was 5-year overall survival (OS). RESULTS: Between January 2007 and July 2010, 52 eligible patients with stage III NPC and 64 eligible patients with nonmetastatic stage IV NPC were accrued to the 2 trials. With a median follow-up of 67 months, the 5-year OS, progression-free survival, distant metastasis-free survival, and local progression-free survival (LPFS) rates were all improved in comparison with historical benchmarks for patients with stage III or IVA/IVB NPC. Multivariate analyses indicated that T and N classifications (T1/T2 vs T3/T4 and N3 vs N0-N2) were the only significant prognosticators for OS. The number of induction chemotherapy cycles was the only significant prognostic factor for predicting LPFS. CONCLUSIONS: TPF-based induction chemotherapy appears to significantly improve outcomes in comparison with historical data when it is administered before CCRT for locoregionally advanced NPC. A phase 3 trial is currently being performed to confirm this benefit. (C) 2017 American Cancer Society.
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study

Shaodong Hong,Yaxiong Zhang,Gengsheng Yu,Peijian Peng,Jiewen Peng,Jun Jia,Xuan Wu,Yan Huang,Yunpeng Yang,Qing Lin,Xuping Xi,Mingjun Xu,Dongping Chen,Xiaojun Lu,Rensheng Wang,Xiaolong Cao,Xiaozhong Chen,Zhixiong Lin,Jianping Xiong,Qin Lin,Conghua Xie,Zhihua Li,Jianji Pan,Jingao Li,Shixiu Wu,Yingni Lian,Quanlie Yang,Chong Zhao,Wenfeng Fang,Li Zhang

DOI: https://doi.org/10.1200/jco.21.00396

IF: 45.3

2021-08-13

Journal of Clinical Oncology

Abstract:PURPOSE GEM20110714 (ClinicalTrials.gov identifier: NCT01528618 ), the first randomized, phase III study of systemic chemotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC), reported significant progression-free survival improvement with gemcitabine plus cisplatin (GP) versus fluorouracil plus cisplatin (FP; hazard ratio, 0.55; 95% CI, 0.44 to 0.68; P < .001). Data from the final analysis of overall survival (OS) are presented here. METHODS From February 2012 to October 2015, 362 patients were randomly assigned to receive either GP (gemcitabine 1 g/m 2 once daily on days 1 and 8 and cisplatin 80 mg/m 2 once daily on day 1; n = 181) or FP (fluorouracil 4 g/m 2 in continuous intravenous infusion over 96 hours and cisplatin 80 mg/m 2 once daily on day 1; n = 181) once every 21 days. The primary end point was progression-free survival, which has been previously reported; OS was a secondary end point. RESULTS After a median follow-up time of 69.5 months with GP and 69.7 months with FP, 148 (81.8%) and 166 (91.7%) deaths occurred in the GP and FP arms, respectively. The estimated hazard ratio for OS was 0.72 (95% CI, 0.58 to 0.90; two-sided P = .004). The median OS was 22.1 months (95% CI, 19.2 to 25.0 months) with GP versus 18.6 months (95% CI, 15.4 to 21.7 months) with FP. The OS probabilities at 1, 3, and 5 years were 79.9% versus 71.8%, 31.0% versus 20.4%, and 19.2% versus 7.8%, respectively. Poststudy therapy was administered in 51.9% and 55.2% of patients in the GP and FP arms, respectively. CONCLUSION Among patients with previously untreated advanced nasopharyngeal carcinoma, those who receive GP have longer OS than those receive FP. Gemcitabine plus cisplatin should be considered a preferred front-line option for these patients.

oncology
Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma

Xue-Song Sun,Xiao-Hao Wang,Sai-Lan Liu,Dong-Hua Luo,Rui Sun,Li-Ting Liu,Shan-Shan Guo,Qiu-Yan Chen,Lin-Quan Tang,Hai-Qiang Mai

DOI: https://doi.org/10.3389/fonc.2020.01295

IF: 4.7

2020-08-06

Frontiers in Oncology

Abstract:Objective: Our study aimed to compare the efficacy and toxicity of two chemotherapy regimens, gemcitabine plus cisplatin (GP) vs. docetaxel plus, fluorouracil plus cisplatin (TPF), in metastatic nasopharyngeal carcinoma (NPC) patients.Methods: We retrospectively enrolled metastatic NPC patients between July 2006 and December 2016 who were treated with TPF or GP palliative chemotherapy (PCT). The association between the PCT regimens and survival conditions was evaluated by log-rank tests and the Cox proportional hazards model. A cohort was created using propensity score matching with the ratio of 1:1 to clarify the results of the multivariable Cox regression analyses. Overall survival (OS) was the primary endpoint.Results: Of 266 eligible patients, 186 and 80 patients, respectively, received TPF and GP regimen. No significant difference was demonstrated in the survival rate between the GP and TPF groups (3-year OS: 52.6 vs. 50.3%; P = 0.929). However, multivariable analysis suggested receiving GP as an independent protective factor (hazard ratio, 0.864; 95% confidence interval, 0.753–0.992; P = 0.042). In the matched cohort, treatment with GP was also associated with a significantly higher OS (3-year OS: 52.6 vs. 35.6%, P = 0.042). Subgroup analysis indicated that the superiority of GP reflected in patients with secondary metastases rather than primary metastases. The incidence of grade 3 to 4 treatment-related toxicity was more common in the TPF group than in the GP group.Conclusion: Our study suggested that GP might be superior to TPF for metastatic NPC patients, especially those with secondary distant metastases. Further studies are necessary to validate our results.

oncology
Clinical Efficacy of Capecitabine Combined with Autologous Cytokine-induced Killer Cells Maintenance Therapy in Treatment of Metastatic Triple Negative Breast Cancer

Shu-xi SONG,Yong-ye LIU,Zhen-yu DING,Hui-ying YU,Ya-ling HAN,Xiao-dong XIE

DOI: https://doi.org/10.3969/j.issn.1002-3429.2015.12.021

2015-01-01

Abstract:Objective To analyze the clinical efficacy and safety of capecitabine combined with autologous cytokine-induced killer cells ( CIK) maintenance therapy in treatment of metastatic triple negative breast cancer ( MTNBC) . Methods The MTNBC patients undergoing capecitabine-based chemotherapy as first line treatment, whose therapeutic effect was SD or above were selected and divided into treatment group and control group randomly. The treatment group received capecitabine maintenance therapy with autologous CIK after the first line treatment. The control group underwent only capecitabine mainte-nance therapy. Baseline assessment was taken 15 d after the end of the last cycle of chemotherapy. The patients were followed up once every two cycles. The median follow-up time was 11. 2 months. T lymphocyte subpopulation in peripheral blood was measured, the side effects, PFS and OS of both groups were observed. Results CD3+CD8+CTL and CD4+CD25+Treg of treatment group were compared at the time of baseline assessment and 1 month after three cycles of chemotherapy. There was no statistically significant difference (P>0. 05). CD3+T, CD3+CD4+Th, CD3+CD56+CIK showed significant im-provement, compared with that before treatment (P<0. 05). The adverse reaction showed that in the treatment group there were 8 patients with fever (18. 2%), and 2 patients in control group (4. 5%). The difference was statistically significant (P<0. 05). The rest (extremities syndrome, drug-induced liver damage, bone marrow suppression and gastrointestinal reac-tion, etc) showed no significant difference. The PFS rate of one year in the two groups was 18. 2% and 9. 1% respectively. The difference was statistically significant (P<0. 05). OS of the two groups was 16. 5 months with no statistically significantdifference (P>0. 05). Conclusion Maintenance therapy of Capecitabine combined with autologous CIK cells in treatment of MTNBC after first-line treatment improves the immune function to enhance the ability of antitumor by natural immunity, which can prolong PFS, and is safe as well. In short, it can improve the therapeutic effect of maintenance therapy in patients with MTNBC.

Structural domains in RNAi

Capecitabine maintenance therapy after induction chemotherapy in newly diagnosed metastatic nasopharyngeal carcinoma: An open-label, randomized, controlled, phase trial.

Meta-Analysis Of Capecitabine-Based Chemotherapy Versus Capecitabine-Free Chemotherapy In Patients With Metastatic Breast Cancer

144O Comparison of Efficacy and Safety of Paclitaxel and Capecitabine Followed by Capecitabine As Maintenance Therapy Versus Cisplatin and Capecitabine Therapy for Advanced Gastric Cancer: a Multicentre, Randomised, Active-Controlled Phase III Study

Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.

WITHDRAWN: Interim Analysis of a Prospective Randomized Non-Inferiority Trial of Cisplatin and Fluorouracil Induction Chemotherapy with or Without Docetaxel in Nasopharyngeal Carcinoma

Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial

Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma.

Effects of Oral Maintenance Chemotherapy and Predictive Value of Circulating EBV DNA in Metastatic Nasopharyngeal Carcinoma

Colour parameters and shade correspondence of CAD-CAM ceramic systems.

Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Recurrent or Metastatic Nasopharyngeal Carcinoma: a Multicentre, Randomised, Open-Label, Phase 3 Trial.

The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial

Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment

Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized controlled phase III trial.

Maintenance intervention to improve survival in patients with metastatic nasopharyngeal carcinoma who benefit from first-line treatment: A prospective multicenter randomized controlled clinical study.

Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma

Maintenance metronomic chemotherapy for metastatic/recurrent nasopharyngeal carcinoma

Effects of Induction Docetaxel, Platinum, and Fluorouracil Chemotherapy in Patients with Stage III or IVA/B Nasopharyngeal Cancer Treated with Concurrent Chemoradiation Therapy: Final Results of 2 Parallel Phase 2 Clinical Trials

Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study

Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma

Clinical Efficacy of Capecitabine Combined with Autologous Cytokine-induced Killer Cells Maintenance Therapy in Treatment of Metastatic Triple Negative Breast Cancer